Pharmaceutical

Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Aug 30, 2023 - 20:00
Codagenix pursues RSV vaccine development amid unexpected challenges
Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.
Read the original article

Tags:

Previous Article

FDA shuns Outlook Therapeutics with wet AMD drug BLA rejection

Next Article

Roche wins first approval for subcutaneous Tecentriq

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Gilead sours on the ‘don’t eat me’ business

STAT+: Gilead sours on the ‘don’t eat me’ business

Feb 11, 2024

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a h...

Dec 9, 2023

STAT+: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs

STAT+: Pharmalittle: How 98 days may cost J&J big bucks...

Sep 2, 2023